Clinical Trial Update: A Study of AAV9 Gene Therapy in Participants With Canavan Disease (CANaspire Clinical Trial) [Phase 1, Phase 2]

View source ↗

Summary

CANaspire study is evaluating an AAV9-mediated gene therapy for Canavan disease and is currently recruiting in Phase 1/2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Canavan Disease

Drugs mentioned

• AAV9 gene therapy for Canavan disease

Snippet

Sponsor: Aspa Therapeutics | Conditions: Canavan Disease | Phase 1, Phase 2 | Status: RECRUITING